Tetraphase Drug Patent Portfolio
Tetraphase owns 1 orange book drug protected by 4 US patents Given below is the list of Tetraphase's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10961190 | Crystalline forms of eravacycline | 19 Oct, 2037 | Active |
| US11578044 | Crystalline forms of eravacycline | 19 Oct, 2037 | Active |
| US8906887 | C7-fluoro substituted tetracycline compounds | 28 Dec, 2030 | Active |
| US8796245 | C7-fluoro substituted tetracycline compounds | 07 Aug, 2029 | Active |
Latest Legal Activities on Tetraphase's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Tetraphase.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| 37 CFR 1.750 Request for reconsideration | 02 Sep, 2025 | US8906887 |
| Notice of Final Determination -Eligible | 05 Jun, 2025 | US8906887 |
| FDA Final Eligibility Letter | 20 May, 2025 | US8906887 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Sep, 2024 | US10961190 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8906887 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US8906887 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 14 Feb, 2023 | US11578044 |
|
Recordation of Patent Grant Mailed
Critical
| 14 Feb, 2023 | US11578044 |
|
Email Notification
Critical
| 26 Jan, 2023 | US11578044 |
|
Issue Notification Mailed
Critical
| 25 Jan, 2023 | US11578044 |
|
Application Is Considered Ready for Issue
Critical
| 09 Jan, 2023 | US11578044 |
| Dispatch to FDC | 09 Jan, 2023 | US11578044 |
|
Issue Fee Payment Received
Critical
| 05 Jan, 2023 | US11578044 |
| Supplemental Papers - Oath or Declaration | 05 Jan, 2023 | US11578044 |
|
Issue Fee Payment Verified
Critical
| 05 Jan, 2023 | US11578044 |
Tetraphase Drug Patents' Oppositions Filed in EPO
Tetraphase drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 18, 2018, by Sandoz Ag. This opposition was filed on patent number EP15180611A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15180611A | Jul, 2018 | Sandoz AG | Revoked |
Tetraphase's Family Patents
Tetraphase Drug List
Given below is the complete list of Tetraphase's drugs and the patents protecting them.
1. Xerava
Xerava is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10961190 | Crystalline forms of eravacycline |
19 Oct, 2037
(11 years from now)
| Active |
| US11578044 | Crystalline forms of eravacycline |
19 Oct, 2037
(11 years from now)
| Active |
| US8906887 | C7-fluoro substituted tetracycline compounds |
28 Dec, 2030
(4 years from now)
| Active |
| US8796245 | C7-fluoro substituted tetracycline compounds |
07 Aug, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xerava's drug page